Analysis Market access

Denmark's Voltabak shortage to mid-May 2027 shows how fragile single-source supply is

DKMA's updated notice on Laboratoires Thea's diclofenac eye drops, with the Methergin withdrawal and estradiol patch notices, shows how Denmark manages supply failures.

VigiEye editorial · Mon 16 Nov 2026

What the notice says

On 13 November 2026 the Danish Medicines Agency (DKMA) updated its supply notice for Voltabak, Laboratoires Thea's diclofenac eye drops. Quality problems are disrupting supply, and the shortage is now expected to run to mid-May 2027. That is roughly six months from the date of the update. DKMA is allowing foreign packs to be supplied under section 29(2) of the Medicines Act.

The records do not say which quality problem is involved, which strengths or pack sizes are affected, or how many patients rely on the product. They also do not say whether the mid-May date is a firm restock forecast or a planning estimate. Teams should treat it as DKMA's current expectation, which the agency may revise again.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Sources this analysis is based on

Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.

More analysis & opinionAll →